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Introduction
Synovial inflammation involving one or more joints is the
presenting feature, and often the predominant clinical mani-
festation of a spectrum of pathologic states, many of which
continue to be incompletely understood. The outcome of
early synovitis can range from rapid and complete resolution
to a persistent inflammatory process associated with irre-
versible articular damage and progressive functional decline.
A rapidly expanding body of information generated from
clinical, epidemiological, and basic research is providing a
deeper understanding of how genetic susceptibility factors
interact in complex ways with diverse environmental
factors, resulting in seemingly related clinical syndromes.
Such clinical syndromes can be thought of as ‘phenocopies’:
in other words phenotypically similar, yet mechanistically
distinct, states. Delineation of the specific molecular path-
ways that underlie disease expression is also linking highly
distinct and seemingly unrelated clinical syndromes. These
disorders are mechanistically similar, yet phenotypically
distinct. These concepts are particularly relevant to under-
standing the spectrum of autoimmunity, chronic inflamma-
tion, and how they intersect to produce synovitis.
In attempting to understand more completely the mecha-
nistic similarities and differences in patients with early
synovitis, an increasing panoply of variables needs to be
considered. Although, to date, no clear model has emerged
upon which to classify early synovitis better, an under-
standing of how these variables interact and intersect will
undoubtedly be of value in delineating the early synovitis
phenocopies.
Clinical patterns and classification
In clinical practice, early synovitis is initially classified on
the basis of the extent, location, and symmetry of the
joint involvement. Although rheumatologists, as a group,
are particularly skilled at this type of pattern recognition,
the etiopathogenic mechanisms determining these pat-
terns of joint involvement are unknown, and therefore
the implications are empiric. Symmetrical involvement of
the wrists and small joints of the hands and feet is highly
characteristic of established rheumatoid arthritis (RA)
and, when present at the onset of the synovitis, suggests
the patient’s symptoms will probably evolve into the
typical RA phenotype, particularly if rheumatoid factor
(RF) is present. The tendency for psoriatic arthritis to
involve the distal interphalangeal joints of the hands, and
to involve multiple joints of a single digit asymmetrically,
is also used as an early classification feature, even in the
absence of any obvious psoriatic plaques. The ‘reactive
arthritis’ syndrome that in some individuals follows
particular genitourinary and gastrointestinal infections
typically features an asymmetric lower extremity oligo-
arthritis. Patients with this articular pattern are often
labeled with this diagnosis, even if an antecedent infec-
tion cannot be identified. Features such as enthesitis,
sacroiliitis, and dactylitis tend to cluster with this
complex of articular inflammation, and collectively form
an overall ‘spondylarthropathy’ pattern.Arthritis Research    Vol 1 No 1 El-Gabalawy
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This informal pattern recognition has been formalized into
criteria sets, which attempt to classify arthritis syndromes,
although not necessarily on a mechanistic basis. The best
validated and most widely used of these criteria sets are
the 1987 American College of Rheumatology (ACR) RA
criteria [1] and the 1991 European Spondylarthropathy
Study Group (ESSG) spondylarthropathy criteria [2].
These criteria sets were developed as a consensus of
expert opinion around patients with well-established and
characteristic clinical features. They are not well suited for
classifying cohorts of early synovitis patients, particularly
if the aim is to identify uniform groups that have a
common pathogenic mechanism and predictable progno-
sis. Indeed, even within the context of what is generally
accepted to be ‘typical’ RA, there is considerable genetic,
pathologic, and immunologic heterogeneity.
Published data from early synovitis cohorts, including our
own at the NIH, indicate that a large percentage of patients
can only be labeled as having ‘unclassified’ or ‘undifferenti-
ated’ arthritis [3–6]. In our cohort, approximately one-third
of the patients who were evaluated within one year of
symptom onset fell into this category, and in some series
this has been as high as 50% [4,7]. It has been stated [8] that
the term ‘undifferentiated’ could have any of the following
implications: 1) an early stage of a well defined rheumatic
disease that will later become differentiated; 2) an abortive
form, or forme fruste, of a well defined rheumatic disease;
3) an overlap syndrome; or 4) a truly unknown, undefined
disease that may be differentiated in the future. Of note,
none of these classifications imply a pathogenic mecha-
nism. The follow-up data that are available from early syn-
ovitis cohorts suggest that most of the undifferentiated
patients remain undifferentiated, but in general tend to
have a favorable prognosis with frequent remission [4,6].
Imaging in the evaluation of early synovitis
Radiographic imaging of articular and periarticular structures
may contribute information that defines specific pheno-
copies more precisely. However, many of the findings such
as soft tissue swelling, periarticular bone loss, new bone for-
mation, and bone erosion may be non-specific. Moreover,
the radiographic findings in patients with early synovitis are
often subtle, confounding diagnostic categorization. In par-
ticular, establishing the unequivocal presence of erosions is
notoriously difficult within the first year of synovitis. The
insensitivity of plain radiography in detecting early erosions
is evident when these techniques are compared to magnetic
resonance imaging (MRI) [9–12]. Furthermore, in addition
to detecting early erosions with a high degree of sensitivity,
MRI is currently the only modality that clearly images the
synovium, allowing the generation of quantitative data
regarding synovial volume and perfusion [13–17]. These
parameters are broadly indicative of the degree of synovial
hyperplasia, infiltration, and proliferation. Longitudinal
studies of inflamed RA joints have shown that the measure-
ment of synovial volume using gadolinium-enhanced MRI
is of value in predicting the subsequent development and
progression of articular erosions [17,18]. This result tends to
confirm the clinical impression that RA joints with a ‘boggy’,
thickened synovium often undergo progressive damage.
MRI has been applied to the task of defining subsets of
early synovitis patients on the basis of the distribution
pattern of the inflammation [19–21]. The data suggest two
principal imaging patterns, one where the inflammatory
changes are based primarily in the synovium, and another
where the periarticular entheses are inflamed in association
with intense edema of the adjacent bone. These two pat-
terns are proposed to broadly classify patients with early
synovitis into an ‘RA’ phenotype where synovitis is the
primary process, and a ‘spondylarthropathy’ phenotype
where enthesitis is the primary process, and synovitis occurs
on a secondary basis. Although the simplicity of this para-
digm is conceptually appealing, it remains to be seen
whether such a ‘tidy’ model will be of value in classifying
the heterogeneous spectrum of patients seen in early syn-
ovitis clinics. It is also not clear whether these MRI patterns
are based on distinct pathogenic mechanisms, as has been
suggested [21]. Interestingly, the limited data available
regarding entheseal pathology suggest a relative paucity of
inflammatory features histologically, a finding which may
itself hint at a unique pathologic process in these structures.
Pathologic features
In view of the widely divergent outcomes associated with
early synovitis, it has been assumed that specific patho-
logic features, or constellations of pathologic features, can
be identified in early synovial tissue samples. Identifica-
tion of these features would allow the definition of distinct
pathogenic mechanisms, and in turn, the definition of
unique phenocopies. The pursuit of this hypothesis has
been facilitated by the more widespread use of closed
needle biopsy and needle arthroscopy techniques. Several
centers, including our own, have undertaken extensive
studies of early synovial tissue samples, taken soon after
the onset of the synovitis, which are analyzed using a
variety of histological and molecular pathology tech-
niques. The patients are then followed longitudinally, and
the pathologic data is related to outcomes. Although many
of these initiatives are still in progress, the published data
do not suggest major differences between early RA syn-
ovitis and other forms of early synovitis, or even between
early and late synovitis [22–24]. The prominence of
plasma cells and macrophages at all stages of RA synovitis
has been noted [25–27]. Indeed, recent data suggest that
synovial macrophage infiltration may occur at a very early,
possibly preclinical, stage in RA [28], and that the degree
of macrophage infiltration may ultimately be an indicator
of the erosive potential of the synovitis [26,27]. Consistent
with this view is mounting evidence that osteoclasts, the
precursors of which are myeloid cells, are likely to be33
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important mediators of bone erosion [29]. It can be specu-
lated that the identification of synovial microenviron-
ments which promote pathways leading to the
differentiation of large numbers of myeloid cells into
osteoclasts would be an important step towards defining
an erosive synovial phenotype pathologically. At present
there is little experimental evidence in this regard.
Infectious agents
Synovitis is clearly associated with a wide spectrum of
infectious agents, and the mechanisms underlying this
association are varied and complex. In the case of septic
arthritis, arguably the best understood of these associa-
tions, a pathogen gains access to the usually sterile syn-
ovial cavity, precipitating an acute monoarticular synovitis
which is predominated by polymorphonuclear leukocytes,
and which is rapidly destructive. Viable organisms are
directly demonstrable in the synovial fluid or tissue, and
the inflammatory process usually resolves completely with
the prompt and successful eradication of the organism. In
general, genetic elements do not appear to play a major
role in the susceptibility to most forms of septic arthritis,
although this has not been extensively studied.
Lyme arthritis is frequently in the differential diagnosis in
patients with early synovitis, particularly in endemic areas.
This disorder has been a good model for understanding the
mechanisms by which microorganisms can interact with the
host’s immune responses to precipitate and perpetuate syn-
ovitis.  Borrelia burgdorferi spirochetes have been demon-
strated in synovial tissue samples obtained early in the
disease, and PCR techniques have further enhanced the
early detection of this organism in synovial tissue and fluid
[30–34]. The chronic arthropathy, typically affecting a
single knee joint, is more suggestive of a persistent local
immune response to bacterial antigens than of a chronic
infectious process. Furthermore, this syndrome demon-
strates an association with HLA-DR4. The histopathologic
features of chronic Lyme synovitis can be indistinguishable
from those of RA [35], although we have observed that
Lyme synovitis tends to feature extensive stromal fibrin
deposits. Of considerable scientific interest has been the
recent observation that individuals with persistent, treat-
ment-resistant Lyme arthritis demonstrate specific T cell
responses to endogenous lymphocyte function associated
antigen (LFA)-1 sequences that are homologous to
sequences in the OSP-A outer membrane protein of Borre-
lia burgdorferi [36]. This apparent molecular mimicry illus-
trates the degree of complexity inherent in the mechanisms
by which microorganisms interact with the host to cause a
persistent inflammatory lesion in the synovium.
The complex interplay between pathogen and host, which
can whimsically be termed ‘the battle of the genomes’, is
particularly relevant to reactive arthritis. In this intriguing
clinical syndrome, there is a clear association with specific
pathogens…sometimes, a clear genetic predilection…some-
times, and complete resolution of the synovitis…most of the
time. In well characterized cases, a lower extremity asym-
metric synovitis, variably associated with enthesitis and
sacroiliitis, typically follows a genitourinary or gastrointesti-
nal infectious syndrome after 2–4 weeks. Yet only a minor-
ity of patients with this pattern of early synovitis have
demonstrable organisms in their urogenital or gastrointesti-
nal tract. Many are labeled as having undifferentiated
arthritis. On the other hand, detailed studies of synovial
samples from the NIH early synovitis cohort have demon-
strated the presence of Chlamydia trachomatis (CT) DNA,
RNA, and antigens, not only in the synovium of patients
with ‘typical’ reactive arthritis, but also in a spectrum of
other synovial tissues, including samples from patients with
RF-positive RA, and even in apparently healthy individuals
[37,38]. In this cohort, synovial cytokine expression profiles
assessed using a nested reverse transcriptase polymerase
chain reaction (RT PCR) technique [39] failed to confirm
the comparatively high interleukin (IL)-4 levels in the syn-
ovium of  reactive arthritis patients that were previously
reported [40]. In agreement with the previous studies, they
did indicate that the synovium of patients with early CT
reactive arthritis, in contrast to that of undifferentiated
arthritis patients with a similar clinical pattern but no syn-
ovial CT, exhibits high levels of both interferon (IFN)-g
and IL-10 [41,42]. Such a cytokine profile has been specu-
lated to play a role in attenuating the expression of specific
CT genes such as MOMP, while promoting the expression
of other genes such as hsp60 [43,44]. Ultimately, this may
result in ineffective elimination of the pathogen.
Interest in a bacterial or viral etiology for RA continues to
wax and wane. Particularly provocative have been recent
studies indicating the presence of parvovirus B19 and
Epstein-Barr virus (EBV) DNA, RNA, and antigens, specif-
ically in the synovium of RA patients [45,46]. In the case of
EBV, this was highly associated with DR4 encoding shared
epitope alleles, suggesting an important immunogenetic
link. As these studies were performed primarily on synovial
samples from patients with long-standing disease, it would
be quite instructive to verify the findings in heterogeneous
early synovitis cohorts. It is possible that, rather than being
specific etiologic agents, these viruses are involved in the
persistence of the synovitis once it is established.
Autoantibodies
It has recently been recognized that, in addition to RF, a
number of antigen–autoantibody systems are highly spe-
cific for RA, and may be of importance both pathogeneti-
cally and prognostically [47]. These systems include the
antifilaggrin (AFA), antikeratin (AKA), antiperinuclear
factor (APF) group, all of which appear to relate to the
presence of citrulline residues in target antigens [48].
Anti-Sa antibodies, also highly specific for RA, identify an
unknown 50 kDa antigen (called Sa) which is present inthe synovium, and may also be citrullinated [49]. Antibod-
ies directed against the protease inhibitor calpastatin (Ra-
1) have been shown to be common in RA sera [50], as have
antibodies directed toward advanced-glycation-endproduct-
modified immunoglobulin G (AGE-IgG) [51]. Ra-33 is
directed towards a spliceosomal ribonucleoprotein, and is
detectable in RA, systemic lupus erythematosus (SLE),
and mixed connective tissue disease (MCTD) patients
[52]. Approximately 10–15% of RA patients demonstrate
antibodies to native collagen II, although these antibodies
are not specific to this arthropathy [53].
Several groups are currently evaluating the diagnostic and
prognostic significance of these autoantibodies in cohorts
of patients with early synovitis. The preliminary findings
from our cohort confirm a strong association of antifilag-
grin and anti-Sa antibodies with RF-positive polyarthritis,
although we identified a number of patients with RF-neg-
ative synovitis, both poly and oligoarticular, who were also
positive for these two antibodies. Moreover, it appears
that anti-Sa antibodies may be associated with a subset of
patients having more severe, erosive RA [54].
Genetics considerations
Studies evaluating genetic association with rheumatic dis-
eases have generally been carried out in populations of
patients with well established, well characterized clinical
syndromes. In the case of RA, the association is based
principally in the class II region of the major histocompati-
bility complex (MHC), a group of at least 50 genes on
human chromosome 6 that encode cell-surface proteins
and that are involved in the immune response to both self
and nonself antigens. The genetic association has been
best explained by the shared epitope (SE) hypothesis [55].
In this model, disease susceptibility and/or severity is
based on the presence of a shared epitope, the QK(R)RAA
amino acid residue sequence in the third hypervariable
region of the DRb1 molecule. The SE sequence is present
in a number of DRB1 alleles, all of which have been indi-
vidually and collectively associated with typical RF-posi-
tive RA. Furthermore, there appears to be an allele dosage
effect, particularly in respect to disease severity [56]. We
have found that the SE alleles, particularly DRB1*0401,
are clearly over-represented in patients with early RF-pos-
itive polyarthritis compared to both other patients with
early synovitis and normal controls [3]. Moreover, we
detect a high degree of association between SE alleles and
the presence of anti-Sa and antifilaggrin antibodies [54].
Interestingly, we were able to show an association
between SE and the presence of early erosions in patients
with RF-negative, but not RF-positive polyarthritis.
Similar data have been generated from the Norfolk Arthri-
tis Registry (Silman A, personal communication).
Based on elegant transgenic animal models [57], an alter-
native hypothesis has been proposed to explain the MHC
class II RA association [58]. This hypothesis suggests that
RA disease susceptibility actually relates to DQ locus
alleles, and that this susceptibility is modified by the
absence of protective (non-SE) DRB1 alleles. The model,
which is harmonious with models of genetic susceptibility
to type I diabetes, has recently been tested in two Euro-
pean RA populations and found to be a good fit with the
epidemiologic data [59], but was not confirmed in another
European study [60]. Analysis of the data from our early
synovitis cohort supports this model, although issues of
linkage dysequilibrium continue to be problematic in
these analyses. These issues have been raised in the
context of several other MHC associations, including
those relating to the tumor necrosis factor (TNF)-a gene.
There is a high degree of association between specific sub-
types of HLA-B27 and the heterogeneous clinical spectrum
of the ‘spondylarthropathies’. It is not yet clear how disor-
ders such as ankylosing spondylitis, reactive arthritis, and
psoriatic arthritis are related pathogenetically, and what role
B27 plays in these mechanisms. The association with axial
manifestations such as sacroiliitis and spondylitis is particu-
larly strong in all of these conditions. Our own data indicate
that B27 is increased in the entire spectrum of early synovi-
tis, including up to 20% of patients with RF-positive pol-
yarthritis, a finding that has been previously reported in a
Finnish RA cohort [61,62]. Moreover, we identified a signifi-
cant association between B27 and SE alleles in the patients
but not in a control population. These observations point to
complex genetic interactions potentially involving extended
‘arthritogenic’ haplotypes, rather than associations of individ-
ual MHC alleles with specific forms of arthritis. The com-
plexity of the genetic associations has been recently pointed
out in experimental arthritis models where disease suscepti-
bility, severity, and chronicity were each shown to be deter-
mined by entirely different regions in the genome [63,64].
Towards a mechanistically based prognostic
model
As data from longitudinal studies of early synovitis cohorts
are gathered, the relative importance of candidate prog-
nostic variables is being clarified. The initial clinical pat-
terns, autoantibody profiles, synovial pathologic features,
cytokine profiles, and gene polymorphisms, among many
other variables, represent variables that are being tested in
robust multivariate models. In addition, the underlying
mechanisms which potentially link these diverse variables
are being explored, both in humans and in animal models.
Ultimately, both the biological and statistical models aim
to define homogeneous patient subsets to which targeted
therapeutic paradigms can be applied. The definition of
meaningful outcomes continues to be challenging, and
recently there has been a shift towards using ambitious
outcome measures such as the achievement of complete
remission, the prevention rather than retardation of
erosive damage, and the maintenance of normal function.
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patients who present with RF-positive symmetrical pol-
yarthritis will probably go on to have persistent, erosive
synovitis associated with a variable degree of disability.
These patients are being targeted for early aggressive
therapies. On the other hand, there is less certainty about
the prognosis of RF-negative polyarthritis. At present it is
not known whether there are common risk factors for bone
erosion that link RF-positive RA, psoriatic arthritis, and
subsets of RF-negative polyarthritis. On the basis of our
own data, and data from other early synovitis cohorts, it
can be proposed that in patients with early RF-negative
polyarthritis, the presence of an RA-associated autoanti-
body such as anti-Sa, antifilaggrin, or anticitrulline, and/or
the presence of one or more SE alleles, is an important
indicator of erosive potential and an unfavorable progno-
sis. These variables can be used to allocate subsets of RF-
negative polyarthritis patients to the same aggressive
therapeutic strategies proposed for RF-positive patients.
Patients who present with oligoarthritis, in general, have
the highest rates of complete resolution of synovitis
within the first months after symptom onset, irrespective
of whether they are labeled as having reactive arthritis or
undifferentiated arthritis. There has been some sugges-
tion that the presence of HLA-B27 in this group of
patients is associated with more persistent synovitis,
although the risk factors for erosive disease remain
entirely unclear. It is possible that the presence of bacter-
ial antigens or bacterial DNA transcripts in the synovium
is a persistence factor. If indeed this is the case, this
group of patients is the best suited for early synovial
biopsy and a broad-based search for microbial antigens
and transcripts in the synovium [65,66]. Despite the fact
that most antibiotic trials of chronic reactive arthritis have
been disappointing so far, there are little data available
regarding how the effects of antimicrobial therapy may
relate to the presence of bacterial antigens and transcripts
in the synovium.
Summary
There is an increasing recognition that patients with synovi-
tis of recent onset have divergent pathogenic mechanisms
underlying what appear to be relatively similar clinical phe-
notypes. There is also a recognition that there are major dif-
ferences in the outcome of early synovitis. The challenge
facing investigators in this area is clarifying how these
mechanisms determine outcome and, in turn, which mech-
anisms are the most appropriate therapeutic targets.
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